Risk factors and outcome of COVID-19 in patients with hematological malignancies

126Citations
Citations of this article
211Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: Prognostic factors of poor outcome in patients with hematological malignancies and COVID-19 are poorly defined. Patients and methods: This was a Spanish transplant group and cell therapy (GETH) multicenter retrospective observational study, which included a large cohort of blood cancer patients with laboratory-confirmed SARS-CoV-2 infection through PCR assays from March 1st 2020 to May 15th 2020. Results: We included 367 pediatric and adult patients with hematological malignancies, including recipients of autologous (ASCT) (n = 58) or allogeneic stem cell transplantation (allo-SCT) (n = 65) from 41 hospitals in Spain. Median age of patients was 64 years (range 1-93.8). Recipients of ASCT and allo-SCT showed lower mortality rates (17% and 18%, respectively) compared to non-SCT patients (31%) (p = 0.02). Prognostic factors identified for day 45 overall mortality (OM) by logistic regression multivariate analysis included age > 70 years [odds ratio (OR) 2.1, 95% confidence interval (CI) 1.2-3.8, p = 0.011]; uncontrolled hematological malignancy (OR 2.9, 95% CI 1.6-5.2, p < 0.0001); ECOG 3-4 (OR, 2.56, 95% CI 1.4-4.7, p = 0.003); neutropenia (< 0.5 × 109/L) (OR 2.8, 95% CI 1.3-6.1, p = 0.01); and a C-reactive protein (CRP) > 20 mg/dL (OR 3.3, 95% CI 1.7-6.4, p < 0.0001). In multivariate analysis of 216 patients with very severe COVID-19, treatment with azithromycin or low dose corticosteroids was associated with lower OM (OR 0.42, 95% CI 0.2-0.89 and OR 0.31, 95% CI 0.11-0.87, respectively, p = 0.02) whereas the use of hidroxycloroquine did not show significant improvement in OM (OR 0.64, 95% CI 0.37-1.1, P = 0.1). Conclusions: In most patients with hematological malignancies COVID-19 mortality was directly driven by older age, disease status, performance status, as well as by immune (neutropenia) parameters and level of inflammation (high CRP). Use of azithromycin and low dose corticosteroids may be of value in very severe COVID-19.

References Powered by Scopus

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

35158Citations
N/AReaders
Get full text

Clinical characteristics of coronavirus disease 2019 in China

21502Citations
N/AReaders
Get full text

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

19972Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study

289Citations
N/AReaders
Get full text

COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)

246Citations
N/AReaders
Get full text

Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Patients after Allogeneic HCT or CD19-based CART therapy—A Single-Center Prospective Cohort Study

123Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Piñana, J. L., Martino, R., García-García, I., Parody, R., Morales, M. D., Benzo, G., … Sureda, A. (2020). Risk factors and outcome of COVID-19 in patients with hematological malignancies. Experimental Hematology and Oncology, 9(1). https://doi.org/10.1186/s40164-020-00177-z

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 40

60%

Researcher 14

21%

Professor / Associate Prof. 10

15%

Lecturer / Post doc 3

4%

Readers' Discipline

Tooltip

Medicine and Dentistry 75

78%

Nursing and Health Professions 8

8%

Biochemistry, Genetics and Molecular Bi... 8

8%

Agricultural and Biological Sciences 5

5%

Save time finding and organizing research with Mendeley

Sign up for free